Quick search:
Result Content Outlet Published Research
Result Content Outlet Published Research
1 Tolebrutinib Effectively Reduces Gadolinium-Enhancing Lesions in Relapsing MS Neurology Advisor 2 months ago
2 Tolebrutinib treatment shows 'dose-dependent reduction' in certain RMS-related lesions Healio 9 months ago
3 Tolebrutinib Appears Promising Against Multiple Sclerosis... : Neurology Today LWW Journals 3 months ago
4 Second BTK Inhibitor, Tolebrutinib, Shows Promise for Relapsing MS Everyday Health 5 months ago
5 Phase 3 Trials of Tolebrutinib in MS Forms to Include Digital Measures Multiple Sclerosis News Today 2 months ago
6 BTK Inhibitor Reduces New Lesions in Relapsing Multiple Sclerosis MedPage Today 5 months ago
7 Neurology Today LWW Journals 3 months ago
8 Sanofi’s Principia purchase fails its first test Vantage 4 months ago
9 Sanofi Genzyme Launches Recruitment Website for Tolebrutinib Trials Multiple Sclerosis News Today 10 months ago
10 MS News That Caught My Eye Last Week: NVG-291, Ocrevus... Multiple Sclerosis News Today 2 months ago
11 Progressive MS Patients Urged to Enroll in Phase 3 Trials of... Multiple Sclerosis News Today 1 year ago
12 Hope Alights at ECTIRMS 2021 as Companies Present New Data BioSpace 3 months ago
13 Glimmers of Hope in MS as Genentech, Sanofi and Biogen Present at ECTRIMS BioSpace 3 months ago
14 Biogen’s search for improved BTK inhibition lands orelabrutinib Vantage 6 months ago
15 Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi Yahoo Finance 2 months ago
16 Bruton's Tyrosine Kinase (BTK) Inhibitor Pipeline Insight Market Report 2021 7 months ago
17 Sanofi (SNY) CEO Paul Hudson Presents at JPMorgan 40th Annual Healthcare Conference (Transcript) Seeking Alpha 5 days ago
18 Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds Multiple Sclerosis News Today 2 months ago
19 Participating in a Clinical Trial – Frequently Asked Questions Multiple Sclerosis News Today 3 months ago
20 Sanofi Shutters Principia's San Francisco Labs After BTK Failure PharmaLive 4 months ago
21 Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020 PRNewswire 1 year ago
22 Gossamer unveils new pipeline plans a year after lead program fizzled out in phase 2 FierceBiotech 3 months ago
23 Year in Review: Multiple Sclerosis | MedPage Today MedPage Today 2 months ago
24 Look back at pharma news in the week to July 16, 2021 The Pharma Letter 6 months ago
25 Clinical Catch-Up: October 11-15 BioSpace 3 months ago
26 Sanofi (SNY) Q2 2021 Earnings Call Transcript The Motley Fool 6 months ago
27 Memory Rehabilitation May Be Beneficial for Patients With Multiple Sclerosis Neurology Advisor 2 months ago
28 Delays hit Sanofi Vantage 3 months ago
29 Biogen's Vumerity and Bristol Myers Squibb's Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established Agents PRNewswire 11 months ago
30 Sanofi delivered close to double-digit Q4 2020 business EPS(1) GlobeNewswire 12 months ago
31 Lemtrada Not Linked to Brain Bleeding in MS Patients, Belgian Study Says Multiple Sclerosis News Today 5 months ago
32 Lilly leads the big pharma pack on pipeline value Vantage 8 months ago
33 Genentech's Ocrevus Dominates the Progressive Multiple Sclerosis Market, Although Emerging Agents Could Threaten its Long-Term Reign, According to Patient Chart Data from Spherix Global Insights PRNewswire 1 year ago
34 Patient Enrollment Concluded Early in PEGASUS Phase 3 GlobeNewswire 1 year ago
35 Principia Biopharma Inc.: Setting The Record Straight On BTK Inhibition Seeking Alpha 2 years ago
36 Sanofi 2020: New challenges – PharmaLive PharmaLive 1 year ago
37 Novartis (NVS) Q3 2021 Earnings Call Transcript Motley Fool 3 months ago
38 Repository Corticotropin Injection Shows Efficacy in Relapsing-Remitting MS Neurology Advisor 3 months ago